{"id":"trifluridine-tipiracil-bevacizumab","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-30%","effect":"Diarrhea"},{"rate":"20-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Vomiting"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL1201583","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Trifluridine/tipiracil is a combination of two drugs that target different steps in the DNA synthesis pathway. Trifluridine is a thymidine analog that is activated by thymidine phosphorylase, which is inhibited by tipiracil. This combination leads to a synergistic effect in inhibiting DNA synthesis in cancer cells. Bevacizumab, on the other hand, targets VEGF-A, a protein that promotes angiogenesis, which is the formation of new blood vessels that supply nutrients to growing tumors.","oneSentence":"Trifluridine/tipiracil is a thymidine kinase 1 inhibitor and tipiracil is a thymidine phosphorylase inhibitor, which work together to inhibit DNA synthesis in cancer cells. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:03.075Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT07491159","phase":"PHASE1, PHASE2","title":"Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-07-01","conditions":"Colorectal Cancer","enrollment":106},{"nctId":"NCT07011550","phase":"PHASE2","title":"Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer","status":"SUSPENDED","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-08-15","conditions":"Microsatellite-stable Colorectal Cancer, Standard of Care, Nivolumab","enrollment":7},{"nctId":"NCT05806931","phase":"PHASE2","title":"Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2023-05-17","conditions":"Colon Cancer, Rectal Cancer","enrollment":50},{"nctId":"NCT06607458","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease","status":"RECRUITING","sponsor":"Delcath Systems Inc.","startDate":"2025-08-05","conditions":"Refractory Metastatic Colorectal Cancer","enrollment":90},{"nctId":"NCT06137170","phase":"","title":"A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-03-01","conditions":"Metastatic Colorectal Cancer","enrollment":121},{"nctId":"NCT05083481","phase":"PHASE1, PHASE2","title":"A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-10-19","conditions":"Advanced Solid Tumors","enrollment":366},{"nctId":"NCT07318389","phase":"EARLY_PHASE1","title":"ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-06-10","conditions":"Dynamic Tumor Resistance, Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT05919264","phase":"PHASE1, PHASE2","title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Parabilis Medicines, Inc.","startDate":"2023-05-23","conditions":"Cancer, Colorectal Cancer, Solid Tumor","enrollment":575},{"nctId":"NCT04109924","phase":"PHASE2","title":"TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-27","conditions":"Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma","enrollment":42},{"nctId":"NCT07381764","phase":"PHASE2","title":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italia Meridionale","startDate":"2026-03-30","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":150},{"nctId":"NCT04626635","phase":"PHASE1, PHASE2","title":"A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-12-21","conditions":"Advanced Solid Tumors","enrollment":933},{"nctId":"NCT07286695","phase":"PHASE2","title":"Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-12-31","conditions":"Metastatic Colorectal Cancer (CRC), Colorectal Cancer","enrollment":292},{"nctId":"NCT07353268","phase":"PHASE2","title":"Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.","status":"NOT_YET_RECRUITING","sponsor":"Tao Zhang","startDate":"2026-01-21","conditions":"Colorectal Cancer","enrollment":76},{"nctId":"NCT04564898","phase":"PHASE1, PHASE2","title":"Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2022-01-25","conditions":"Colorectal Cancer Metastatic","enrollment":48},{"nctId":"NCT05405595","phase":"PHASE1, PHASE2","title":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Adagene Inc","startDate":"2022-06-15","conditions":"Advanced/Metastatic Solid Tumors","enrollment":186},{"nctId":"NCT03869892","phase":"PHASE3","title":"Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2019-03-21","conditions":"Metastatic Colorectal Cancer","enrollment":856},{"nctId":"NCT06856837","phase":"PHASE2","title":"- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2025-10-27","conditions":"Metastatic Colorectal Cancer","enrollment":140},{"nctId":"NCT06245356","phase":"PHASE2","title":"Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-03-21","conditions":"Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency","enrollment":73},{"nctId":"NCT07261709","phase":"PHASE2","title":"Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-12-01","conditions":"Refractory Metastatic Colorectal Cancer","enrollment":236},{"nctId":"NCT05839951","phase":"","title":"An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-04-24","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":818},{"nctId":"NCT05029882","phase":"PHASE1","title":"Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2021-10-13","conditions":"Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma","enrollment":520},{"nctId":"NCT06699836","phase":"PHASE2","title":"A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC","status":"RECRUITING","sponsor":"CytoDyn, Inc.","startDate":"2025-06-16","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":60},{"nctId":"NCT07171554","phase":"NA","title":"Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Oncosyne AS","startDate":"2025-09","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":75},{"nctId":"NCT06887218","phase":"PHASE2","title":"5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-05-08","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":57},{"nctId":"NCT06614192","phase":"PHASE3","title":"A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-11-08","conditions":"Metastatic Colorectal Cancer","enrollment":460},{"nctId":"NCT06764680","phase":"PHASE2","title":"Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12-31","conditions":"Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy","enrollment":57},{"nctId":"NCT07138885","phase":"PHASE2","title":"A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Hepatocellular Carcinoma (HCC), Second Line Treatment","enrollment":62},{"nctId":"NCT07116577","phase":"PHASE2","title":"Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC","status":"NOT_YET_RECRUITING","sponsor":"Jinan Central Hospital","startDate":"2025-08-31","conditions":"mCRC","enrollment":37},{"nctId":"NCT07085169","phase":"PHASE2","title":"Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-08-01","conditions":"Colo-rectal Cancer, Third-line and Beyond Therapy, TAS 102","enrollment":50},{"nctId":"NCT07071844","phase":"PHASE2","title":"BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-09","conditions":"Metastatic Colorectal Cancer","enrollment":162},{"nctId":"NCT06873763","phase":"PHASE1, PHASE2","title":"Nelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer","status":"RECRUITING","sponsor":"STCube, Inc.","startDate":"2025-06-09","conditions":"Metastatic Colorectal Cancer (CRC), Recurrent Colorectal Cancer","enrollment":52},{"nctId":"NCT07012954","phase":"PHASE1, PHASE2","title":"ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-01","conditions":"Colorectal Cancer Metastatic","enrollment":64},{"nctId":"NCT05854498","phase":"PHASE2","title":"Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-10-13","conditions":"Metastatic Colorectal Cancer","enrollment":25},{"nctId":"NCT06992648","phase":"PHASE3","title":"Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-04-01","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Recurrent","enrollment":302},{"nctId":"NCT05312398","phase":"PHASE2","title":"CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2021-07-15","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":219},{"nctId":"NCT05848739","phase":"PHASE1","title":"A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Sapience Therapeutics","startDate":"2023-06-05","conditions":"Colon Cancer, Metastatic Colon Cancer","enrollment":130},{"nctId":"NCT06882915","phase":"PHASE1","title":"Efficacy and Safety of Trifluridine/tipiracil (TAS-102) Combined with Bevacizumab and Putalimab in the Treatment of Patients with MCRC After Cytoreductive Surgery: a Single-arm, Single-center Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-05-01","conditions":"Colorectal Cancer (CRC)","enrollment":20},{"nctId":"NCT06872606","phase":"PHASE2","title":"Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-04-01","conditions":"Rectal Adenocarcinoma","enrollment":33},{"nctId":"NCT06522919","phase":"PHASE2","title":"Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-01-07","conditions":"Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer","enrollment":36},{"nctId":"NCT06711471","phase":"PHASE2","title":"Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer","status":"RECRUITING","sponsor":"LIN YANG","startDate":"2024-11-14","conditions":"Gastric Cancer Adenocarcinoma Metastatic","enrollment":31},{"nctId":"NCT04999761","phase":"PHASE1","title":"AB122 Platform Study","status":"RECRUITING","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2021-06-01","conditions":"Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer","enrollment":917},{"nctId":"NCT04737187","phase":"PHASE3","title":"Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2020-11-25","conditions":"Refractory Metastatic Colorectal Cancer","enrollment":492},{"nctId":"NCT06403709","phase":"PHASE2","title":"Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-08-01","conditions":"Metastatic Colorectal Cancer","enrollment":35},{"nctId":"NCT01916447","phase":"PHASE1","title":"A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.","status":"COMPLETED","sponsor":"Taiho Oncology, Inc.","startDate":"2013-09","conditions":"Advanced Gastrointestinal Tumors","enrollment":65},{"nctId":"NCT06563986","phase":"PHASE2","title":"FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2024-06-18","conditions":"Metastatic Colorectal Cancer","enrollment":40},{"nctId":"NCT02743221","phase":"PHASE2","title":"A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2016-04-29","conditions":"Metastatic Colorectal Cancer","enrollment":154},{"nctId":"NCT02848443","phase":"PHASE1","title":"Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2016-05","conditions":"Metastatic Colorectal Cancer","enrollment":78},{"nctId":"NCT05189171","phase":"","title":"MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer","status":"COMPLETED","sponsor":"Xilis, Inc.","startDate":"2022-10-25","conditions":"Colorectal Neoplasms","enrollment":46},{"nctId":"NCT04054908","phase":"","title":"Gut Microbiome in Colorectal Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2018-04-13","conditions":"Gastrointestinal Microbiome, Neoplasm, Colorectal","enrollment":50},{"nctId":"NCT06202001","phase":"PHASE1, PHASE2","title":"Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-10-01","conditions":"Metastatic Colorectal Cancer","enrollment":70},{"nctId":"NCT06293014","phase":"PHASE2","title":"TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-02-23","conditions":"Colorectal Cancer","enrollment":224},{"nctId":"NCT05007132","phase":"PHASE2","title":"Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2021-12-17","conditions":"Metastatic Colorectal Cancer","enrollment":153},{"nctId":"NCT06242067","phase":"PHASE2","title":"Second-line Treatment of Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-04-23","conditions":"Metastatic Colorectal Cancer","enrollment":50},{"nctId":"NCT06060704","phase":"PHASE2","title":"Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-11","conditions":"Metastatic Colorectal Cancer","enrollment":33},{"nctId":"NCT06039202","phase":"PHASE2","title":"Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Holy Stone Healthcare Co., Ltd","startDate":"2024-01","conditions":"Metastatic Colorectal Cancer","enrollment":100},{"nctId":"NCT06031376","phase":"","title":"Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC","status":"COMPLETED","sponsor":"Hunan Cancer Hospital","startDate":"2019-07-01","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":106},{"nctId":"NCT05869097","phase":"","title":"Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hunan Cancer Hospital","startDate":"2020-11-01","conditions":"Metastatic Colorectal Adenocarcinoma","enrollment":90},{"nctId":"NCT05314101","phase":"PHASE2","title":"TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2022-04-01","conditions":"Immunotherapy, Colorectal Cancer","enrollment":25},{"nctId":"NCT04683965","phase":"PHASE2","title":"Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-01-01","conditions":"Colorectal Neoplasms","enrollment":27},{"nctId":"NCT05364489","phase":"PHASE2","title":"Efficacy, Safety and Exploratory Clinical Study of Bevacizumab Combined With Oxaliplatin and TAS-102 in First-line Treatment of Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2022-06-15","conditions":"Advanced Colorectal Cancer","enrollment":20},{"nctId":"NCT05077839","phase":"PHASE2","title":"Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-09-01","conditions":"First-line Treatment, Advanced Colorectal Cancer","enrollment":184},{"nctId":"NCT02654639","phase":"PHASE2","title":"Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2016-02","conditions":"Metastatic Colorectal Cancer","enrollment":4}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Trifluridine/tipiracil + bevacizumab","genericName":"Trifluridine/tipiracil + bevacizumab","companyName":"Second Affiliated Hospital, School of Medicine, Zhejiang University","companyId":"second-affiliated-hospital-school-of-medicine-zhejiang-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Trifluridine/tipiracil is a thymidine kinase 1 inhibitor and tipiracil is a thymidine phosphorylase inhibitor, which work together to inhibit DNA synthesis in cancer cells. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis. Used for Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}